Key result
CAD shows no association with serum telomerase concentration or hTERT gene expression vs. controls.
Why the study?
Telomerase activity and hTERT gene expression in patients with ACS and SCAD compared to controls were not well characterized, nor was their association with mortality.
Does serum telomerase activity or hTERT gene expression differ between patients with acute coronary syndrome, stable coronary artery disease, and healthy controls, and does it predict mortality?
Cohort (n=211)
Does serum telomerase activity or hTERT gene expression differ between patients with acute coronary syndrome, stable coronary artery disease, and healthy controls, and does it predict mortality?
Peripheral blood telomerase activity and hTERT gene expression are not significantly altered in patients with acute or stable coronary artery disease compared to controls, and do not appear to predict all-cause mortality.
Serum telomerase and hTERT levels should not guide CAD assessment; leaves open their role in other cardiovascular phenotypes.
BACKGROUND: In this study, we aimed to examine the telomerase activity and hTERT gene expression in patients with acute coronary syndrome (ACS) and those with stable coronary artery disease (SCAD) and compare the results to controls. Additionally, we compared overall mortality rates relative to the telomerase activity. METHODS: A total of 211 patients (78 ACS and 71 SCAD patients) were included in the study. The telomerase concentration was measured by ELISA and used to determine telomerase activity. The hTERT gene expression was determined by real-time PCR. RESULTS: The serum telomerase enzyme concentration was lower in ACS (36.61 ± 1.54) and SCAD (36.79 ± 1.57) when compared to the control group (37.03 ± 2.25). However, this difference did not reach statistical significance (p = 0.890). The hTERT gene expression acting in telomerase enzyme synthesis was 2.7-fold lower in ACS group (p = 0.070) and 2.2-fold lower in the SCAD group (p = 0.101) compared to the control group. Patients were followed for a median of 32 months (minimum: 0.1, maximum: 46.8). The serum telomerase concentrations in patients who died and those survived in the SCAD group (35.98 ± 2.02 vs 36.86 ± 1.52 ng/ml, respectively; p = 0.529) were similar to those in the ACS group (36.39 ± 1.08 vs 36.63 ± 1.60 ng/ml, respectively p = 0.993). CONCLUSIONS: In the current study, telomerase activity or hTERT expression was similar in patients with ACS, SCAD, and controls. Moreover, telomerase activity was not associated with all- cause mortality during the 32-month follow-up (Tab. 3, Fig. 1, Ref. 29).
No takes yet. Share an insight, caveat, or question.
Kılınç et al. (2024) conducted a cohort in Coronary artery disease (Acute coronary syndrome and Stable coronary artery disease) (n=211). Coronary artery disease (ACS and SCAD) vs. Normal coronary arteries or lesions less than 20% (Control) was evaluated on Serum telomerase enzyme concentration (ng/ml) (p=0.974). Coronary artery disease was not associated with significant differences in serum telomerase enzyme concentration (36.69 vs 37.03 ng/ml, p=0.974) or hTERT gene expression compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: